Getting Inside: Improving Oral Bioavailability Quiz

Lipinski's Rule of Five is a heuristic used to evaluate "druglikeness." A Log P greater than 5 indicates the molecule is highly hydrophobic. While this helps with membrane permeability, it often leads to poor aqueous solubility in the intestinal lumen, meaning the drug cannot dissolve sufficiently to be absorbed, thus lowering overall bioavailability.

This is false. The primary goal of ester prodrugs in oral delivery is to mask polar groups (like carboxylic acids). By increasing the lipophilicity, the drug can more easily partition into and pass through the lipid bilayers of the intestinal wall via passive diffusion, thereby increasing the fraction of the dose that reaches the systemic circulation.

After absorption from the gut, drugs travel via the portal vein directly to the liver. If the liver possesses high metabolic activity toward the drug (Phase I or II metabolism), a significant portion of the dose is deactivated before it ever reaches the systemic circulation. Prodrugs are often designed to "mask" the sites where these metabolic enzymes act.

P-gp is an efflux pump that "spits" drugs back into the intestinal lumen. To overcome this, chemists can modify the drug so it no longer fits the P-gp binding site, or they can "camouflage" the drug as a nutrient (like an amino acid) to use an active transport uptake system that P-gp doesn't recognize.

Acyclovir has poor oral absorption. By attaching the amino acid L-valine, the molecule mimics a dipeptide. This allows it to be recognized by the high-capacity PEPT1 transporter in the intestine. Once absorbed, systemic esterases cleave the valine, releasing the active drug. This "hijacking" of natural transport systems significantly boosts plasma levels.

This is true. Bioavailability is a balance between solubility and permeability. If a drug is so lipophilic that it won't dissolve in the aqueous environment of the GI tract, it will pass through the body without being absorbed. Increasing solubility (e.g., by forming a salt or a polar prodrug) ensures the drug is available in solution at the surface of the intestinal membrane.

The BCS is a regulatory tool that classifies drugs into four classes based on their solubility and permeability. Class I drugs (high solubility, high permeability) are ideal for oral delivery. Class IV drugs (low both) are the most challenging. Understanding where a lead compound falls in this matrix guides the medicinal chemist on whether to focus on increasing lipophilicity or solubility.

Salts (like hydrochloride or sodium salts) dissociate into ions in water. This significantly increases the dissolution rate—the speed at which the solid drug turns into a dissolved solute. Since only dissolved drugs can be absorbed, faster dissolution leads to a higher concentration gradient across the intestinal membrane and better absorption.

Phosphate groups are highly polar and ionized at physiological pH. If an active drug is too "greasy" to dissolve in the gut, adding a phosphate group makes it highly water-soluble. Once it reaches the intestinal brush border, alkaline phosphatase enzymes remove the phosphate, allowing the now-lipophilic drug to diffuse through the membrane.

This is true. While the liver is the main site of metabolism, the cells lining the small intestine (enterocytes) also contain high levels of CYP3A4 enzymes. These enzymes can begin deactivating the drug before it even enters the bloodstream. This "pre-hepatic" metabolism is a major reason why some drugs have very low oral bioavailability despite high absorption rates.

While Log P helps permeability, excessive "greasiness" causes problems. The drug may become insoluble in the gut, stick to albumin in the blood (reducing the free, active fraction), or hide in fat cells where it cannot reach the target. Highly lipophilic drugs are actually excreted slower by the kidneys because they are easily reabsorbed.

Bioavailability (F) is expressed as a fraction. A value of 0.05 means only 5% of the swallowed dose reaches the systemic circulation. This indicates a massive loss of the drug, either because it never dissolved, it couldn't cross the membrane, or it was destroyed by enzymes in the gut wall or liver during its first pass.

Fragment-based lead discovery uses much smaller molecules than typical drugs. The Rule of Three suggests that these fragments should have a molecular weight

This is correct. If a drug is acid-labile, it may break down before reaching the small intestine. Designing a prodrug that is stable at low pH but releases the drug at the neutral pH of the intestine (or after absorption) is a valid way to ensure the active therapeutic reaches the systemic circulation intact.

Bioequivalence is a regulatory standard. It ensures that a generic version of a drug reaches the bloodstream at the same rate and to the same extent as the brand-name version. If the "Area Under the Curve" (AUC) and the "Peak Concentration" (Cmax) are statistically similar, the two products are considered bioequivalent and can be used interchangeably.